A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

September 26, 2016

Study Completion Date

September 26, 2016

Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS)
Interventions
DRUG

PF-04958242

Administered as specified in the treatment arm

DRUG

placebo

placebo, twice daily (BID) for 12 weeks, capsule

Trial Locations (16)

20877

CBH Health, LLC, Gaithersburg

30331

Atlanta Center For Medical Research, Atlanta

38119

Research Strategies of Memphis, LLC, Memphis

60169

Alexian Brothers Centers for Psychiatric Research, Hoffman Estates

Chinmay K. Patel, D.O., Hoffman Estates

70629

Lake Charles Clinical Trials, Lake Charles

75243

Pillar Clinical Research, LLC, Dallas

90502

Collaborative Neuroscience Network, LLC, Torrance

92056

Excell Research, Inc, Oceanside

92102

California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego

92845

Collaborative Neuroscience Network, LLC (Investigator Site File Location), Garden Grove

Collaborative Neuroscience Network, LLC, Garden Grove

92868

NRC Research Institute, Orange

98007

Northwest Clinical Research Center, Bellevue

08009

Hassman Research Institute, Berlin

08053

CRI Worldwide, LLC, Marlton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY